A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors

M. Mita, M. Gordon, N. Rejeb, A. Gianella-Borradori, V. Jego, A. Mita, J. Sarantopoulos, K. Sankhala, D. Mendelson

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences